Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
SPRAVATO® is the only FDA-approved prescription nasal spray for Treatment-resistant depression (TRD), Major Depressive Disorder (MDD), Anxiety, PTSD, chronic pain and more. It’s active ingredient is esketamine, a derivative of the anesthetic ketamine. It’s used to treat certain forms of depression in adults, especially cases where standard treatments haven’t worked. It is an NDMA receptor antagonist that is believed to work differently by acting on a pathway in the brain that affects glutamate.
If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD).
It might be time to talk to your doctor about a different treatment approach. See what makes SPRAVATO® different and learn more about other patients’ experiences with SPRAVATO®.
Treatment-Resistant Depression (TRD)
For adults with Major Depressive Disorder who have tried at least two different antidepressants without adequate improvement.
Major Depressive Disorder (MDD) with Acute Suicidal Thoughts or Behavior
For adults with Major Depressive Disorder who have tried at least two different antidepressants without adequate improvement.
Especially when:
• Episodes are frequent
• Symptoms are debilitating
• Hospitalization risk is high
Spravato can help reduce depressive symptoms quickly while other treatments are adjusted.
While not separately FDA-approved for these as standalone diagnoses, clinicians may consider it when depression is part of:
Severe, Recurrent Depression
Especially when:
• Episodes are frequent
• Symptoms are debilitating
• Hospitalization risk is high
Depression with Strong Anhedonia
When patients report:
• Emotional numbness
• Inability to feel pleasure
• Lack of motivation
Spravato’s glutamate-based mechanism can sometimes help where SSRIs didn’t.
Depression with Prominent Anxiety
If someone has:
• MDD + significant anxiety
• Poor response to traditional antidepressants
(It’s not an anxiety medication, but sometimes helps when anxiety is tied to resistant depression.)
Rapid Symptom Relief Situations
Because it can work faster than traditional antidepressants, it may be considered when:
• Someone needs quicker symptom reduction
• There’s concern about safety due to severity
Please reach us at hello@ivevolutionmed.com if you cannot find an answer to your question.
There is a study that suggests after the third oral antidepressant, remission rates dropped below 14%. If you’ve tried two or more oral antidepressants and are still experiencing depressive symptoms, you may have treatment-resistant depression and it may be time for something different.
Treatment-resistant depression is defined as not responding to two or more antidepressants of adequate dose and duration. If your doctor has diagnosed you with treatment-resistant depression, you may benefit from treatment with a different kind of medication.
SPRAVATO® may be an option for adults with treatment-resistant depression or major depressive disorder with suicidal thoughts who have not responded to traditional antidepressants. A comprehensive evaluation is required to determine if treatment is safe and appropriate for you. Contacts us for a consult!
It is important to understand the potential side effects of any medication you consider taking. To help ensure safety, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
SPRAVATO® is available here at our office in Syosset and must be self-administered under the supervision of a healthcare provider.
SPRAVATO® (esketamine) may be covered by insurance, but approval depends on your specific plan and medical history. Contact us for more information.
Please contact us is you have any other questions. We'd love to be a part of your wellness journey
IV Evolution
65 Berry Hill Rd, Syosset, NY 11791
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.